Skip to main content
Clinical Trials/NCT00082485
NCT00082485CompletedPhase 2

Multi-Center Trial of Baclofen for the Treatment of Cocaine Dependence

National Institute on Drug Abuse (NIDA)8 sites in 1 country160 target enrollmentStarted: June 2004Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
160
Locations
8
Primary Endpoint
Effects of medication on cocaine craving

Study Overview

Brief Summary

The purpose of this study is to assess the efficacy and safety of baclofen for the treatment of cocaine dependence.

Detailed Description

Double-blind, placebo-controlled, parallel design trial of baclofen for the treatment of cocaine dependence

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 99 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Subject must have DSM-IV diagnosis of cocaine dependence.
  • Subject must be seeking treatment for cocaine dependence.
  • Be be able to verbalize understanding of consent form, provide written consent and verbalize willingness to complete study procedures.

Exclusion Criteria

  • Please contact site for more information.

Arms & Interventions

2

Placebo Comparator

Intervention: Placebo (Other)

1

Active Comparator

Intervention: Baclofen (Drug)

Outcomes

Primary Outcomes

Effects of medication on cocaine craving

Secondary Outcomes

No secondary outcomes reported

Investigators

Study Sites (8)

Loading locations...

Similar Trials

Baclofen for the Treatment of Cocaine... | Clinical Trial